Induced Pluripotent Stem Cells
GMP iPSC reprogramming, gene editing and differentiation
Leading Industry Experts
OmniaBio has generated and characterized over 200 induced pluripotent stem cell (iPSC) lines. This deep expertise ensures we can meet the unique requirements of each client. Our team of iPSC industry leaders take a personalized approach to each project and can help you at every step.
iPSC CDMO Offerings
- Good Manufacturing Practices (GMP)-compliant reprogramming platforms to produce therapeutic-grade iPSC lines
- Expertise using a variety of different nucleases and delivery methods, including CRISPR-Cas9, to generate gene-edited iPSC lines with knock-in, knock-out, and single nucleotide polymorphism (SNP) modifications
- An optimized screening approach for fast and accurate identification of single-cell clones of interest
- Process scale-up for the generation of a variety of differentiated cell types
- An in-house analytics platform to enable cell line characterization
Services for Your Project Phase
Process
Development
Experts in optimization to ensure reliable scale-up to produce cell and gene therapies.
GMP
Manufacturing
Our state-of-the-art facility is equipped with the tools and flexibility to manufacture your product at commercial scale.
Analytical
Development
Providing a robust suite of analytical capabilities that are integrated through your product’s lifecycle to support the development process.
Regulatory
Support
With in-depth knowledge, we can guide you through the regulatory landscape to approval.
Our Expertise on Demand
Related Thought Leadership & Resources
Blog
iPSCs are created by reprogramming differentiated somatic cells, which allows them to exhibit properties similar to embryonic stem cells. From a scale-up and manufacturing perspective, groups need the right support to achieve their goals in a time-efficient and cost-effective manner.
Transcript
As the number of iPSC-based therapies in clinical development is increasing, the industry is seeing significant advancement following decades of the industry’s iPSC development efforts.
Technical Poster
This technical application poster shares data demonstrating that SOLUPORE® technology, a non-viral system and novel transfection platform, efficiently produces single and multi-gene edited induced pluripotent stem cells (iPSCs).